Neovasc Inc (NASDAQ:NVCN) (TSE:NVC) saw unusually-high trading volume on Wednesday . Approximately 6,123,039 shares traded hands during mid-day trading, an increase of 222% from the previous session’s volume of 1,900,017 shares.The stock last traded at $0.54 and had previously closed at $0.41.

NVCN has been the topic of a number of analyst reports. Zacks Investment Research cut Neovasc from a “hold” rating to a “sell” rating in a research note on Wednesday, March 27th. ValuEngine cut Neovasc from a “buy” rating to a “hold” rating in a research note on Monday, February 4th.

The company has a market capitalization of $26.35 million, a price-to-earnings ratio of -0.20 and a beta of 1.59.

Neovasc (NASDAQ:NVCN) (TSE:NVC) last issued its quarterly earnings results on Thursday, March 21st. The medical equipment provider reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.02). The company had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $0.60 million. On average, equities research analysts forecast that Neovasc Inc will post -0.25 EPS for the current year.

A hedge fund recently bought a new stake in Neovasc stock. Virtu Financial LLC acquired a new position in shares of Neovasc Inc (NASDAQ:NVCN) (TSE:NVC) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 63,055 shares of the medical equipment provider’s stock, valued at approximately $38,000. Virtu Financial LLC owned 0.27% of Neovasc at the end of the most recent quarter. 4.64% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at

About Neovasc (NASDAQ:NVCN)

Neovasc Inc, a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products.

See Also: Derivative

Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with's FREE daily email newsletter.